BidaskClub Upgrades Vital Therapies, Inc. (VTL) to Strong-Buy
Vital Therapies, Inc. (NASDAQ:VTL) was upgraded by research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.
Separately, Zacks Investment Research lowered shares of Vital Therapies from a “hold” rating to a “sell” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $8.00.
Shares of Vital Therapies (NASDAQ VTL) traded up 5.22% on Thursday, hitting $6.05. The company had a trading volume of 127,883 shares. The stock’s market cap is $255.35 million. Vital Therapies has a 12 month low of $2.25 and a 12 month high of $6.58. The company has a 50-day moving average of $3.99 and a 200 day moving average of $3.43.
Vital Therapies (NASDAQ:VTL) last released its earnings results on Thursday, August 3rd. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.01. During the same quarter last year, the business earned ($0.30) EPS. Analysts anticipate that Vital Therapies will post ($1.31) EPS for the current fiscal year.
In other news, Director Muneer A. Satter purchased 50,000 shares of Vital Therapies stock in a transaction that occurred on Friday, September 8th. The stock was acquired at an average price of $3.53 per share, for a total transaction of $176,500.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Jean Jacques Bienaime purchased 10,000 shares of Vital Therapies stock in a transaction that occurred on Wednesday, September 13th. The stock was purchased at an average price of $4.00 per share, with a total value of $40,000.00. Following the transaction, the director now owns 65,119 shares in the company, valued at approximately $260,476. The disclosure for this purchase can be found here. Over the last three months, insiders have purchased 190,000 shares of company stock valued at $737,800. Company insiders own 32.60% of the company’s stock.
Several large investors have recently modified their holdings of the stock. FMR LLC lifted its position in shares of Vital Therapies by 102.9% in the 1st quarter. FMR LLC now owns 2,957,878 shares of the company’s stock valued at $11,832,000 after acquiring an additional 1,500,000 shares in the last quarter. Victory Capital Management Inc. lifted its position in shares of Vital Therapies by 1.2% in the 2nd quarter. Victory Capital Management Inc. now owns 2,579,279 shares of the company’s stock valued at $7,480,000 after acquiring an additional 29,840 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vital Therapies by 261.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 233,250 shares of the company’s stock valued at $676,000 after acquiring an additional 168,705 shares in the last quarter. UBS Oconnor LLC purchased a new stake in shares of Vital Therapies in the 1st quarter valued at approximately $800,000. Finally, LMR Partners LLP purchased a new stake in shares of Vital Therapies in the 2nd quarter valued at approximately $396,000. Institutional investors and hedge funds own 25.58% of the company’s stock.
Vital Therapies Company Profile
Vital Therapies, Inc is a biotherapeutic company. The Company is focused on developing a human hepatic cell-based treatment targeting acute forms of liver failure. Its product candidate, the ELAD System, is an extracorporeal human allogeneic cellular liver therapy designed to allow the patient’s liver to regenerate to a healthy state, or to stabilize the patient until transplant.
Receive News & Ratings for Vital Therapies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vital Therapies Inc. and related companies with MarketBeat.com's FREE daily email newsletter.